title: Targeting Iron Deficiency Anemia in Heart Failure.
abstract: Iron deficiency is common in heart failure (HF) patients, and is associated with increased risk of adverse clinical outcomes. Clinical trials of intravenous iron supplementation in iron-deficient HF patients have demonstrated short-term improvement in functional capacity and quality of life. In some trials, the benefits of iron supplementation were independent of the hemoglobin levels. Additional investigations of iron supplementation are needed to characterize the mechanisms contributing to clinical benefit and long-term safety in HF.
authors.affiliation: Leon H. Charney Division of Cardiology, New York University Langone Medical Center, New York, NY.
authors.forename: Tajinderpal
authors.initials: T
authors.lastname: Saraon
authors.affiliation: Leon H. Charney Division of Cardiology, New York University Langone Medical Center, New York, NY. Electronic address: Stuart.Katz@nyumc.org.
authors.forename: Stuart D
authors.initials: SD
authors.lastname: Katz
mesh_terms: D061605:Administration, Intravenous; D018798:Anemia, Iron-Deficiency / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005296:Ferrous Compounds / Q000008:administration & dosage*; D005937:Glucaric Acid / Q000008:administration & dosage*; D006333:Heart Failure / Q000503:physiopathology; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D015201:Meta-Analysis as Topic; D015995:Prevalence; D014131:Trace Elements / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States
chemical_list: D005290:Ferric Compounds; D005296:Ferrous Compounds; D006397:Hematinics; D014131:Trace Elements; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; C031621:ferrous fumarate; C011819:ferrous gluconate
keywords: Clinical trials; Heart failure; Intravenous iron; Iron homeostasis